683 Capital Management’s Marker Therapeutics MRKR Stock Holding History

683 Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-56,000	Closed	-$4.43M	–	162
2019 Q2	$4.43M	Sell	56,000 -90,000	-62%	-$5.35M	0.4%	54
2019 Q1	$9.64M	Hold	146,000	–	–	0.87%	31
2018 Q4	$8.1M	Buy	146,000 +136,000	+1,360%	+$9.91M	0.49%	44
2018 Q3	$905K	Sell	10,000 -10,000	-50%	-$859K	0.06%	100
2018 Q2	$1.89M	Buy	+20,000	New	+$1.02M	0.13%	87

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

683 Capital Management's MRKR Position: Q3 2019 in Review

683 Capital Management sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 56,000 shares — an estimated $4.43M sold.

683 Capital Management first reported a position in MRKR in Q2 2018 and held it in 5 quarters. The position peaked at $9.64M in Q1 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

683 Capital Management reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
683 Capital Management sold 56,000 Marker Therapeutics shares in Q3 2019, an estimated $4.43M.
683 Capital Management first reported a position in Marker Therapeutics in Q2 2018 and held it in 5 quarters.
683 Capital Management's Marker Therapeutics position peaked at $9.64M in Q1 2019.
73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on 683 Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.